Annalisa De Silvestri

Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis

Abstract Background Multiple advanced therapies are available for moderate-to-severe ulcerative colitis (UC), but comparative efficacy data are limited. We compared the 1-year efficacy and safety of 7 therapies: the anti-tumor necrosis factor agents infliximab, adalimumab, and go...

Predicting long-term survival in primary myelofibrosis

We interrogated data from 217 subjects with primary myelofibrosis (PMF) diagnosed before 2001 to identify covariates at diagnosis associated with long-term survival. Forty-one survived more than 25 years. Long-term survivors were more often female, younger than 50 years and less...